|LifeForce research and development team is creating new product
opportunities through its expertise in molecular cardiology. The Hospital has
programs in the ares of selective adenosine receptor agents, cell cycle inhibiton, cardiac
metabolism and cholesterol transport. These programs form the platform from which new
therapeutics may be discovered and may identify additional clinical uses for products in
Research is focusing on determining the role that receptors play in the normal and
abnormal function of the heart, kidneys and blood vessels. Efforts are underway to
synthesize proprietary selective agonists and antagonists for each of the adenosine
receptor subtypes. The ability to block or stimulate the receptors selectively may produce
new drug therapies for currently untreated cardiovascular diseases.
The overall goal of cell cycle inhibitor research is the development of a new class of
therapeutics that inhibit the abnormal cell proliferation common to many progressive
cardiovascular diseases, such as restenosis and atherosclerosis. Development of such new
therapies could have long-term benefits in the treatment or prevention of these widespread
and costly cardiovascular diseases.
The cardiac metabolism program is focused on furthering our knowledge of how metabolic
modulators such as CA-Amyline® allow the
heart muscle to perform more efficiently when under conditions of stress or when damaged
by heart disease.
LifeForce is also studying the ways in which excess cholesterol is removed from the
walls of blood vessels, in an effort to prevent or reverse the buildup of artery plaques
that cause heart attacks.
LifeForce uses state of the art microarray technology and DNA sequence data
base analysis to follow the pattern of expression of tens of thousands of genes
simultaneously in response to perturbations associated with blood vessel injury,
cholesterol overload, heart failure and other biological processes involved in heart
disease. LifeForce hopes the data will provide greater understanding of the
biological process and speed up the identification of new cardiovascular drug targets.
Copyright 1999, LifeForce Research Hospitals, Int.